Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 9/20 | 0.68 |
| ▸ | F2 | P00734 | 7/20 | 0.62 |
| ▸ | PLG | P00747 | 1/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.62 |
| ▸ | C1S | P09871 | 1/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7388981 | 0.85 | PRSS1 (0.70) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL7381578 | 0.84 | F2 (0.58) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL1820723 | 0.82 | PRSS1 (0.66) | PRSS1F2PLGPRSS2PRSS3 | |
| SCHEMBL7387777 | 0.81 | PRSS1 (0.63) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL7386374 | 0.81 | PRSS1 (0.56) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL7389290 | 0.81 | PRSS1 (0.56) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL12989513 | 0.80 | PRSS1 (1.00) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL14599537 | 0.80 | PRSS1 (1.00) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL14599539 | 0.80 | PRSS1 (1.00) | PRSS1F2PLGPRSS2C1S | |
| SCHEMBL7870926 | 0.79 | TSHR (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | PRSS1 2062/4885F2 3712/4885PLG 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.